Unbound MEDLINE

Abdominal sacrocolpopexy: anatomic outcomes and complications with Pelvicol, autologous and synthetic graft materials. American journal of obstetrics and gynecology [Am J Obstet Gynecol] Journal article

 
TitleAbdominal sacrocolpopexy: anatomic outcomes and complications with Pelvicol, autologous and synthetic graft materials.
Author(s)Quiroz LH, Gutman RE, Shippey S, Cundiff GW, Sanses T, Blomquist JL, Handa VL 
InstitutionDepartment of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. lquiroz1@jhmi.edu
SourceAm J Obstet Gynecol 2008 May; 198(5):557.e1-5.
MeSHAdult
Aged
Fascia
Female
Gynecologic Surgical Procedures
Humans
Middle Aged
Prostheses and Implants
Reoperation
Retrospective Studies
Sacrum
Surgical Mesh
Suture Techniques
Treatment Outcome
Uterine Prolapse
Vagina
AbstractOBJECTIVE: The purpose of this study was to compare anatomic outcomes and graft-related complications (GRCs) for abdominal sacrocolpopexy (ASC) with Pelvicol (CR BARD, Murray Hill, NJ), autologous fascia, and synthetic grafts.
STUDY DESIGN: This is a retrospective cohort study of ASC from 2001-2005. We reviewed anatomic outcomes and GRCs. Apical failure was defined as >stage 0.
RESULTS: Of 259 ASC procedures, Pelvicol was used in 102 procedures (39%); synthetic mesh in 134 procedures (52%), and autologous fascia in 23 procedures (9%). Mean postoperative follow up was 1.1 years. Apical failure by graft group were Pelvicol 10 (11%), synthetics 1 (1%), and autologous 1 (7%; P = .011). All 7 reoperations for apical prolapse were in the Pelvicol group. GRCs occurred in 16% of the cases, with a higher proportion of erosions in the Pelvicol group (11% vs 3% and 4%; P = .045). Reoperations as a result of GRC were similar between groups.
CONCLUSION: ASC is more likely to fail with Pelvicol than with synthetic or autologous grafts. The use of Pelvicol did not reduce graft-related complications in this population.
Languageeng
Pub Type(s)Comparative Study
Journal Article
PubMed ID18455533
  
Advertise on this site.